AtriCure, Inc. (NASDAQ:ATRC) Stock Holdings Lessened by US Bancorp DE

US Bancorp DE reduced its stake in shares of AtriCure, Inc. (NASDAQ:ATRC) by 32.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 997 shares of the medical device company’s stock after selling 469 shares during the quarter. US Bancorp DE’s holdings in AtriCure were worth $28,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of the stock. Comerica Bank boosted its position in AtriCure by 70.5% during the first quarter. Comerica Bank now owns 2,522 shares of the medical device company’s stock valued at $77,000 after purchasing an additional 1,043 shares during the last quarter. Quest Partners LLC raised its stake in shares of AtriCure by 38.3% during the 2nd quarter. Quest Partners LLC now owns 5,868 shares of the medical device company’s stock worth $134,000 after purchasing an additional 1,626 shares in the last quarter. nVerses Capital LLC lifted its holdings in shares of AtriCure by 733.3% during the 3rd quarter. nVerses Capital LLC now owns 5,000 shares of the medical device company’s stock valued at $140,000 after buying an additional 4,400 shares during the last quarter. Mount Yale Investment Advisors LLC increased its position in AtriCure by 32.1% during the second quarter. Mount Yale Investment Advisors LLC now owns 9,743 shares of the medical device company’s stock worth $222,000 after buying an additional 2,368 shares during the last quarter. Finally, ProShare Advisors LLC lifted its holdings in AtriCure by 8.5% in the 1st quarter. ProShare Advisors LLC now owns 8,371 shares of the medical device company’s stock worth $255,000 after purchasing an additional 659 shares during the last quarter. 99.11% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. JPMorgan Chase & Co. upped their price target on AtriCure from $30.00 to $40.00 and gave the stock an “overweight” rating in a report on Wednesday, October 30th. BTIG Research decreased their price target on shares of AtriCure from $58.00 to $53.00 and set a “buy” rating on the stock in a research report on Wednesday, July 31st. Needham & Company LLC boosted their price objective on shares of AtriCure from $34.00 to $40.00 and gave the stock a “buy” rating in a report on Wednesday, October 30th. Oppenheimer upped their price objective on shares of AtriCure from $32.00 to $36.00 and gave the company an “outperform” rating in a research report on Wednesday, October 30th. Finally, Canaccord Genuity Group lifted their target price on AtriCure from $49.00 to $53.00 and gave the stock a “buy” rating in a research report on Wednesday, October 30th. One analyst has rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat, AtriCure has a consensus rating of “Moderate Buy” and a consensus price target of $43.11.

AtriCure Stock Down 0.9 %

Shares of ATRC opened at $34.72 on Tuesday. The company has a quick ratio of 2.59, a current ratio of 3.62 and a debt-to-equity ratio of 0.13. The company has a 50-day moving average price of $30.08 and a two-hundred day moving average price of $25.43. The stock has a market cap of $1.69 billion, a price-to-earnings ratio of -41.83 and a beta of 1.41. AtriCure, Inc. has a 12 month low of $18.94 and a 12 month high of $43.00.

AtriCure (NASDAQ:ATRC) last posted its earnings results on Tuesday, October 29th. The medical device company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.19) by $0.02. The business had revenue of $115.91 million during the quarter, compared to the consensus estimate of $112.23 million. AtriCure had a negative return on equity of 8.12% and a negative net margin of 8.70%. AtriCure’s revenue was up 17.9% on a year-over-year basis. During the same quarter last year, the company earned ($0.20) EPS. Equities analysts predict that AtriCure, Inc. will post -0.72 EPS for the current fiscal year.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.